Search hospitals > Connecticut > Fairfield

Smilow Cancer Hospital Care Center-Fairfield

Claim this profile
Fairfield, Connecticut 06824
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
98 reported clinical trials
38 medical researchers
Photo of Smilow Cancer Hospital Care Center-Fairfield in FairfieldPhoto of Smilow Cancer Hospital Care Center-Fairfield in FairfieldPhoto of Smilow Cancer Hospital Care Center-Fairfield in Fairfield

Summary

Smilow Cancer Hospital Care Center-Fairfield is a medical facility located in Fairfield, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Smilow Cancer Hospital Care Center-Fairfield is involved with conducting 98 clinical trials across 265 conditions. There are 38 research doctors associated with this hospital, such as Alessandro Santin, Amer M. Zeidan, Joseph W. Kim, MD, and Jeremy S. Kortmansky.

Area of expertise

1Cancer
Global Leader
Smilow Cancer Hospital Care Center-Fairfield has run 39 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
ER positive
2Breast Cancer
Global Leader
Smilow Cancer Hospital Care Center-Fairfield has run 22 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Smilow Cancer Hospital Care Center-Fairfield

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Cancer
Squamous Cell Carcinoma
Prostate Cancer
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Neuroendocrine Carcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Smilow Cancer Hospital Care Center-Fairfield?
Smilow Cancer Hospital Care Center-Fairfield is a medical facility located in Fairfield, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Smilow Cancer Hospital Care Center-Fairfield is involved with conducting 98 clinical trials across 265 conditions. There are 38 research doctors associated with this hospital, such as Alessandro Santin, Amer M. Zeidan, Joseph W. Kim, MD, and Jeremy S. Kortmansky.